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Milk protein hydrolysates generated with different starting substrates, including sodium caseinate 
(NaCN), acid casein (Acid CN), skim milk powder (SMP) and glycomacropeptide (GMP) were 
demonstrated to behave as serotonin 2C (5-HT2c) receptor agonists. The 5-HT2c receptor activating 
potential of NaCN hydrolysates correlated with an increased protein hydrolysis, most likely due to 10 
enhanced release of bioactive peptides over the time course of hydrolysis. In its unhydrolysed form, GMP 
was the only starting substrate showing 5-HT2c serotonin receptor agonist activity. The 5-HT2c serotonin 
receptor agonist activity of its corresponding hydrolysate (GMPH-240 min) was significantly higher (P < 
0.05). Fractionation of the 240 min NaCNH using ultrafiltration (UF), solid-phase extraction (SPE), semi-
preparative reverse-phase high performance liquid chromatography (RP-HPLC) and isoelectric focusing 15 
(IEF) was carried out. Characterisation of the fractions obtained shows that the bioactive peptides had a 
relatively low molecular mass (< 1 kDa), were hydrophobic in nature and had a pI between 8.6 and 13.2. 
These different physicochemical characteristics together with the stability of NaCNH-240 min to 
simulated intestinal digestion, allow prediction of a favourable outcome regarding the bioavailability of 
the bioactive peptides therein. These results reinforce the potential of milk-derived bioactive peptides to 20 
be developed into functional foods targeted at 5-HT2c receptor modulation. 
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1. Introduction 
Alarming data for obesity incidence have been reported 25 
worldwide.1 In 2008, it was reported that 1.5 billion adults were 
overweight, of which 500 million were obese.2 In 2010, it was 
estimated that 43 million children under the age of five were 
overweight. In the European Union, it is estimated that 35.9 % of 
adults are overweight and 17.2 % are obese, with a higher 30 
proportion of males being overweight compared to females.3 
Excess weight has been associated with negative health 
consequences including impaired glucose metabolism, together 
with dyslipidemia and hypertension, conditions which are 
generally categorised under the metabolic syndrome.1,4,5 35 
Reduction of body mass can be achieved by decreasing food 
intake and increasing calorie expenditure through physical 
activity. Nevertheless, this can constitute challenging alterations 
in the lifestyle of people who need to lose weight. Different 
strategies to counteract obesity have been proposed, these include 40 
modification of the diet combined with exercise and bariatric 
surgery.1,6-8 In addition, several anti-obesity pharmaceutical drugs 
have been developed over the past decade. However, most 
candidates have so far failed to reach the market, due to safety 
concerns and side effects. 9-20 Currently, the only FDA-approved 45 
drug in the treatment of obesity is the over-the-counter available 
oral lipase inhibitor, orlistat (Xenical ®; FDA approved 2007), 
albeit it is not as effective as other drugs in reducing body weight. 
Changes in diet, exercise and the pharmaceutical approach only 
allow short term reduction of body weight which generally does 50 
not last beyond a year often due to non-compliance of overweight 
people.1 Weight loss strategies aimed at dietary alterations are 
still preferred over pharmacotherapies and are a lower risk 
alternative to bariatric procedures.1 The inclusion of natural 
substances with appetite lowering properties in the diet have been 55 
proposed.21-25 Weight loss can be achieved by a modulation of 
appetite and satiety through the central nervous system (CNS) 
involving increased serotonin (5-hydroxytryptamine) 
neurotransmission.26-30 In addition, it has been established that 
central regulation of appetite can be achieved through 5-HT2C 60 
serotonin receptor agonism.6,31 Expression of the 5-HT2C 
serotonin receptors has been linked with suppression of appetite, 
reinforcing its role in body weight management. 30 Different 
serotonergic drugs targeting the CNS, including sibutramine, 
fluoxetine, m-chlorophenylpiperazine (mCPP) and d-65 
fenfluramine, all act as appetite suppressants.32,33 In addition, 
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specific drugs targeting serotonin receptors have also been 
developed to regulate appetite.6 However, these drugs often only 
give modest effects and the risks do not always outweigh the 
health benefits. Heart and pulmonary vasculature side-effects 
have been associated with non-specific effects, including off-5 
target activation of other serotonin receptors (5-HT2A and 5-
HT2B).
6,30,31,34,35 Therefore, agonists which can selectively bind 5-
HT2C receptors while minimising side-effects would be beneficial 
for weight management. Currently, the first 5-HT2C receptor 
specific drug, Lorcaserin, has been developed and is awaiting 10 
FDA approval.7,8,36,37 Development of non-pharmacological 
compounds from natural sources with serotonergic properties 
may help to avoid the side effects associated with the utilisation 
of synthetic drugs. 
 Milk has been associated to satiating properties and more 15 
particularly, milk proteins have been described as being more 
satiating than milk fats or carbohydrates.24,25,38 Satiety signals 
following protein intake occur in the gastrointestinal tract 
inducing slower gastric emptying, stimulation of gut hormone 
receptors and possibly opioid receptors.38  Numerous biologically 20 
active peptides are encrypted within the primary structures of 
milk proteins.39-42 Bioactive milk peptides have been described as 
potential health promoting and disease risk reducing agents. 
Targeted utilisation of these peptides can beneficially modulate 
physiological systems within the human body. A diverse range of 25 
potential physiological targets have been identified, mostly using 
in vitro assays to date, for milk bioactive peptides. These include 
immunomodulatory, opioid, mineral binding/bone formation, 
hypotensive, antithrombic, anticancer, etc, properties.39,43,44 The 
influence of whey protein intake on different satiating hormones 30 
has been reviewed by Luhovyy et al.24 Milk bioactive peptides 
developed as natural ingredients with serotonin agonist properties 
have potential as weight loss management ingredients which 
could be incorporated in the diet. This may help to alleviate 
issues encountered with weight reducing drugs where compliance 35 
to the treatment can become an issue.35 
 The aim of this study was to investigate the potential of milk 
derived peptides to activate the 5-HT2C receptor in an in vitro 
cell-based assay system. The 5-HT2C receptor belongs to the 
family of G protein coupled receptors operating via the Gq 40 
signalling pathway. Activation of Gq induces the stimulation of 
phospholipase C, which leads to an increase in inositol 
triphosphate and elevation in intracellular Ca2+.6,45,46 
Identification of 5-HT2C receptor agonists can be achieved using 
fluorescent based assays to quantify an increase in intracellular 45 
calcium. Milk-derived hydrolysates were manufactured using a 
food-grade protocol with the view of developing ingredients for 
use in food-formulations. Hydrolysates arising from different 
casein-derived substrates were evaluated in vitro for their agonist 
properties towards 5-HT2C serotonin receptors. Different 50 
fractionation protocols were applied to a bioactive sodium 
caseinate hydrolysate (NaCNH-240 min) in order to selectively 
separate bioactive peptides from inactive peptides. Fractionation 
was carried out based on molecular mass, hydrophobicity or 
isolectric point differences with the view to better understanding 55 
the physicochemical properties of the bioactive peptides therein. 
2. Materials and methods 
2.1. Reagents 
Trifluoroacetic acid (TFA), phosphoric acid (H3PO4) and 5–
hydroxytryptamine were obtained from Sigma Aldrich (Dublin, 60 
Ireland). Hydrochloric acid (HCl), sodium hydroxide (NaOH), 
HPLC grade water and acetonitrile (ACN) were from VWR 
(Dublin, Ireland). Solid-phase extraction (SPE) cartridges (Giga 
Tube StrataX, 33µm, 85Å Polymeric RP 1 g / 12 mL) were 
obtained from Phenomenex (Cheshire, UK). The calcium 65 
sensitive fluorescent Ca4 dye was obtained from Molecular 
Devices Corporation (Sunnyvale, CA, USA). Human embryonic 
kidney 293 (HEK 293A) cells were from Invitrogen (Carlsbad, 
CA, USA). Hanks balanced salt solution (HBSS) and HEPES 
buffer were from Gibco (Grand Island, NY, USA). The skim milk 70 
powder (SMP, 25.8 % (w/w) protein), sodium caseinate (NaCN, 
90.4 % (w/w) protein), acid casein (Acid CN, 89.0 % (w/w) 
protein) and glycomacropeptide (GMP) were obtained from 
commercial suppliers. Corolase PP was obtained from AB 
enzymes (Darmstadt, Germany). 75 
2.2. Hydrolysis of milk protein substrates and 
physicochemical characterisation of the hydrolysates 
Hydrolysis of milk protein substrates 
A schematic representation of the experimental procedure is 
given in Fig. 1. The starting substrates NaCN, Acid CN, and SMP 80 
were resuspended at 10 % (w/w) on a protein basis in water. 
GMP was resuspended at 10 % (w/w) powder in water. These 
solutions were dispersed under agitation at 50C for 1 h using an 
overhead stirrer (Heidolph RZR 1, Germany). The protein 
solutions were adjusted to pH 2.0 prior to hydrolysis using an 85 
aqueous solution of 1.0 N HCl. A control sample was removed 
from the protein dispersion and maintained at 50°C for the 
duration of the hydrolysis reaction. NaCN, Acid CN, SMP and 
GMP were hydrolysed with pepsin at an enzyme to substrate ratio 
(E:S) of 1 % (w/w), pH 2.0, 50°C. Hydrolysis was conducted at a 90 
constant pH of 2.0 using a pH Stat (Titrando 843, Tiamo 1.4 
Metrohm, Dublin, Ireland). For the NaCN hydrolysate, samples 
were withdrawn at different time intervals (10, 30, 60, 120 and 
240 min) whereas hydrolysate samples for Acid CNH-240 min, 
GMPH-240 min and SMPH-240 min were withdrawn at 240 min. 95 
The enzyme was inactivated by heating at 90°C for 20 min and 
the samples were subsequently freeze-dried (FreeZone 18L, 
Labconco, Kansas City, U.S.A.) and stored at -20°C until 
utilisation. 
Simulated intestinal digestion  100 
In order to study the stability of the bioactive peptides within 
NaCNH-240 min, simulated intestinal digestion (SID) was 
carried out according to Walsh et al.47 Freeze-dried NaCNH-240 
min was resuspended in water at 2 % (w/v) on a protein basis at 
37C for 30 min. Hydrolysis of NaCNH-240 min was carried out 105 
at 37°C for 150 min at pH 7.5 with Corolase PP (E:S, 1.0 %). The 
enzyme was inactivated by heating at 90°C for 20 min and the 
samples were freeze-dried and stored at -20°C until utilisation. 
Reverse-phase high performance liquid chromatography 
(RP-HPLC), RP-ultra-performance liquid chromatography 110 
(RP-UPLC) and molecular mass distribution of peptides and 
proteins 
Unhydrolysed milk protein (NaCN), hydrolysate sample 
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(NaCNH) and fractions obtained following ultrafiltration (UF) of 
NaCNH-240 min were analysed by RP-HPLC with a liquid 
chromatograph (Waters, Dublin, Ireland) mounted with a 250 x 
4.6 mm I.D., 5.0 µm particle size Jupiter C18 column attached to 
a C18 guard column (4 x 3 mm I.D., Phenomenex, Cheshire, 5 
UK). Detection of peptides and proteins was carried out at 214 
nm. Separation of the peptides was carried out as described in 
Spellman et al.48 
 Milk proteins (NaCN, Acid CN, SMP and GMP), hydrolysates 
(NaCNH, Acid CNH-240 min, SMPH-240 min and GMPH-240 10 
min), SPE fractions and isoelectric focusing (IEF) fractions of 
NaCNH-240 min were analysed by liquid chromatography using 
a UPLC (Acquity, Waters, Dublin, Ireland) as described by 
Nongonierma and FitzGerald49. Separation of peptides and 
individual milk proteins was carried out at 30C, using a 2.1 x 15 
100 mm, 1.7 µm Acquity UPLC C18 BEH column mounted with 
a 0.2 µm inline filter (Waters, Dublin, Ireland). Detection of 
peptides and proteins was carried out at 214 nm. 
 The molecular mass distribution profiles of the proteins and 
peptides present in the NaCN, NaCNH and associated UF 20 
fractions of NaCNH-240 min sample were determined by gel 
permeation chromatography – high performance liquid 
chromatography (GPC-HPLC) essentially as described by 
Spellman et al.48 The freeze-dried samples were resuspended in 
the mobile phase (0.1 % (v/v) TFA in 30 % HPLC grade ACN in 25 
HPLC grade water at a concentration of 0.25 % (w/v) and filtered 
through 0.2 µm PTFE filters (VWR, Dublin, Ireland). A 600 x 
7.5 mm I.D. TSK G2000 SW column attached to a 75 x 7.5 mm 
I.D. TSKgel SW guard column (Tosoh Bioscience, Stuttgart, 
Germany) was used for the separation. Analysis of the samples 30 
was carried out in isocratic mode at a flow rate of 0.5 mL.min-1 
and the absorbance was monitored at 214 nm. 
 
 
 35 
 
 
 
 
 40 
 
 
 
 
 45 
 
Fig 1: Schematic representation of hydrolysis of the different milk protein 
substrates and simulated intestinal digestion and fractionation of the 
sodium caseinate hydrolysate (NaCNH-240 min). NaCN: sodium 
caseinate; Acid CN: acid casein; SMP: skim milk powder; GMP: 50 
glycomacropeptide; RP-HPLC: reverse-phase-high performance liquid 
chromatography; UF: ultrafiltration; SPE: Solid-phase extraction; IEF: 
isoelectric focusing.  
2.3. Fractionation of NaCNH-240 min 
Hydrolysate sample NaCNH-240 min was fractionnated by UF, 55 
SPE, semi-preparative RP-HPLC and IEF in order to isolate 
bioactive fractions present in this hydrolysate. 
UF fractionation 
NaCNH-240 min was fractionated using a UF unit (Sartoflow 
Alpha filtration system, Sartorius, Germany). Fractionation was 60 
carried out using two different membranes having 5 and 1 kDa 
nominal molecular weight cut-off (MWCO) values. The four 
fractions (permeates and retentates) collected were freeze-dried 
and stored at -20°C until utilisation. 
SPE fractionation 65 
NaCNH-240 min was resuspended in HPLC grade water at a 
concentration of 0.5 % (w/v) and applied on a Giga tube Strata X 
cartridge as described by Nongonierma and FitzGerald.49 The 
SPE cartridge was connected to a manifold (Phenomenex, 
Cheshire, UK) to extract the different fractions under vacuum (15 70 
mmHg). The procedure followed with the SPE cartridge was a 
modification of the fractionation technique described by Herraiz 
et al.50 A volume of 30 mL NaCNH-240 min filtrate was slowly 
applied at the top of the SPE cartridge to allow adsorption of the 
peptides. The SPE cartridge was washed with water to remove 75 
any unbound material. Stepwise elution with different solutions 
of 5 to 50 % (v/v) ACN in water were used to desorb the peptides 
from the SPE cartridge. This extraction procedure was repeated 3 
times and the fractions eluted at the same ACN gradient were 
pooled. The eleven fractions generated were evaporated in a 80 
solvent evaporator (Genevac, EZ-2 Plus, Genevac Ltd., Ipswich, 
UK). 
Semi-preparative RP-HPLC fractionation 
Fractionation of NaCNH-240 min was carried out by semi-
preparative RP-HPLC (Waters. Dublin, Ireland). NaCNH-240 85 
min was resuspended at a concentration of 10 % (w/v) in HPLC 
grade water and 500 µL were injected on a C18 semi-preparative 
column (250 × 15mm I.D., 10 µm particle size, Phenomenex, 
Cheshire, UK) attached to a C18 guard column (Phenomenex, 
Cheshire, UK). Mobile phase A was HPLC grade water and 90 
phase B was 100 % (v/v) ACN. The flow rate was set at 6 
mL.min-1 and separation of the peptides was carried out using the 
following linear gradient : 0–8 min: 100 % A; 8–80 min: 100–30 
% A; 80–85 min: 30-0 % A; 85–90 min 0 % A; 90-95 min: 0-100 
% A; 95-100 min 100 % A. The absorbance of the eluent was 95 
monitored at 214 nm. Eleven fractions were collected with a 
fraction collector (Waters, Dublin, Ireland) during each run. The 
semi-preparative procedure was carried out six times and 
fractions from the runs were pooled. The different fractions were 
evaporated in a solvent evaporator. 100 
IEF fractionation 
IEF was carried out using a Rotofor cell (Bio-Rad, Hercules, CA, 
USA) with the 5 kDa permeate of NaCNH-240 min (1.7 % w/v) 
resuspended in distilled water containing 2.75 mL ampholyte 
Biolyte 3/10 (Bio-Rad, Alphatech, Wicklow, Ireland). The 105 
cathode and anode compartments of the Rotofor cell were filled 
with 0.1 M NaOH and H3PO4 solutions, respectively. Separation 
of peptides was carried out at 15 W constant power for 4 h at 
4C. These settings allowed migration of acidic peptides to the 
anode and basic peptides to the cathode until they reach their 110 
zwitterionic state and stabilize at a pH corresponding to their 
isoelectric point.51,52 Twenty different peptide fractions were 
collected and pooled depending on their pH value to make up 
four final fractions. The four fractions were freeze dried and 
stored at −18°C. 115 
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2.4. Determination of 5-HT2c receptor activation with the 
different milk protein hydrolysates and NaCNH-240 min 
fractions 
The medium-throughput cellular based screening assay used in 
this study measured receptor mediated calcium uptake with a 5 
commercially available calcium sensitive fluorescent Ca4 dye. 
HEK 293A cells were stably transfected with two isoforms of the 
the 5-HT2C receptor, the unedited 5-HT2C–INI and partially edited 
5-HT2C-VSV isoform. The partly edited 5-HT2C–VSV, results from 
the distinctive ability of the 5-HT2C receptor to be modified by 10 
post-transcriptional RNA editing 53 and is the most abundantly 
expressed 5-HT2C receptor isoform in human brain regions, 
particularly in the hypothalamus.54,55 In addition, increased 
editing of the 5-HT2C receptor has been associated with an altered 
feeding behaviour and fat mass, which supports the role of the 5-15 
HT2C in obesity.
30,56,57 Stably transfected HEK 293A cells were 
seeded in 96 well plates at a density of 2.5 x 105 cells.mL-1 at 100 
µL/well. Growth medium was removed after 24 h at 37°C, 5% 
CO2 and cells were incubated with 25 µL of the assay buffer, 
containing HBSS supplemented with 20 mM HEPES buffer, and 20 
25 µL of Ca4 dye according to the manufacturer’s protocol. 
Agonists (10 nM) and milk protein hydrolysates (0.005 to 1 
mg.mL-1) were resuspended in assay buffer. Addition of assay 
buffer as blank control, endogenous ligand 5–hydroxytryptamine 
(5HT) as positive control and hydrolysate test solutions (25 25 
µL/well) was performed using the Flexstation II. Fluorescence 
readings were taken for 160 s in flex mode with excitation and 
emission wavelength of 485 and 525 nm, respectively. The 
relative increase in intracellular calcium (Ca2+) was calculated as 
the difference between maximum and baseline fluorescence 30 
(Vmax-Vmin). Unstimulated baseline emission obtained with the 
assay buffer was subtracted from ligand-induced emission and 
depicted as percentage relative fluorescent units (RFU) compared 
to the maximal calcium influx obtained by the 5HT positive 
control. Each agonist dose response curve was constructed using 35 
ExcelTM software. 
2.5. Statistical analysis  
Mean multi comparison was carried out using a one way 
ANOVA followed by a Student Newman-Keuls test with SPSS 
(version 9, SPSS Inc., Chicago, IL, USA) at a significance level P 40 
< 0.05. 
3. Results 
3.1. Influence of hydrolysis time on serotonergic properties of 
NaCNH 
The molecular mass distribution of NaCN and the different 45 
NaCNH was determined (Fig. 2 a).  
The GPC results showed that degradation of the different caseins 
present in NaCN (proteinaceous material > 10 kDa) occurred 
during the time course of hydrolysis. The proportion of 
proteinaceous material decreased from 68.1 to 23.6 % between 10 50 
and 240 min hydrolysis while the proportion of peptides less than 
1 kDa increased from 3.8 to 20.2 % during the same time (Fig. 
2a). NaCNH still contained some unhydrolysed caseins after 240 
-
-casein) were seen on the RP-HPLC profile of the NaCN 55 
substrate (Fig. 3a). After 240 min hydrolysis, the caseins were 
degraded following the hydrolytic activity of the enzyme, which 
resulted in the appearance of various peptide peaks on the RP-
HPLC profile of NaCN-240 min (Fig. 3b). Unhydrolysed NaCN 
induced a small increase in intracellular calcium with 5-HT2C-60 
INI serotonin receptor whereas no change in intracellular calcium 
was seen with 5-HT2C-VSV serotonin receptor (Fig. 2b). 
However, compared to NaCN, a greater increase in the 
intracellular calcium was seen with the different NaCNH (Fig. 
2b). No calcium increase was seen in untransfected Hek293A 65 
cells, not expressing the 5-HT2C receptor (data not shown). Over 
the time course of hydrolysis, serotonin 5HT2C receptor 
mediated intracellular calcium increased from 49.1 ± 8.9 to 70.6 
± 14.6 % and from 38.3 ± 5.9 to 61.9 ± 8.9 % between 10 and 
240 min with 5-HT2C-INI and 5-HT2C-VSV, respectively (Fig. 70 
2b). 
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Fig 2: (a) Molecular mass distribution profiles and (b) relative increase in 
5-HT2C receptor mediated intracellular Ca
2+ in human embryonic kidney 
293 (HEK 293A) cells. NaCN: unhydrolysed sodium caseinate, NaCNH x 
min: sodium caseinate hydrolysate withdrawn at x min, Ret:  retentate 
obtained following ultrafiltration (UF) of NaCNH- 240 min, Perm: UF 100 
permeate of NaCNH- 240 min. In Fig. 2b, values with different 
superscript letters are significantly different (P < 0.05). 
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Fig 3: Reverse-phase high performance liquid chromatography (RP-
HPLC) profiles of unhydrolysed sodium caseinate (NaCN), sodium 
caseinate hydrolysates withdrawn at 240 min (NaCNH-240 min) and 
ultra-filtration (UF) fractions. (a) NaCN (b) NaCNH-240 min (c) 5 kDa 
permeate and (d) 1 kDa permeate. 1- -casein, 2- s2-casein, 3- s1-5 
casein, 4- -casein. 
3.2. Influence of the starting substrate on serotonergic 
properties of milk protein hydrolysates  
Three other starting substrates (Acid CN, GMP and SMP) were 
hydrolysed for 240 min. Three of the substrates allowed 10 
generation of hydrolysates (NaCNH-240 min, Acid CNH-240 
min and GMPH-240 min) with agonistic properties on the 5-HT2C 
serotonin receptor. Intracellular calcium increase was higher with 
GMPH-240 min than with Acid CNH-240 min (Table 1). 
Interestingly, unhydrolysed GMP also behaved as an agonist for 15 
the 5-HT2C serotonin receptor. However, the calcium increase 
measured with GMPH-240 min was significantly higher than that 
with GMP (P < 0.05). With SMPH-240 min, agonist properties 
were only observed with 5-HT2C-INI, whereas intracellular 
calcium increase with 5-HT2C-VSV was relatively low (Table 1). 20 
The low bioactivity observed with SMPH-240 min was probably 
due to the fact that this hydrolysate contains a lower 
concentration of bioactive peptides on a weight basis compared to 
the other hydrolysates. In fact, SMP contains 3 times less protein 
compared to NaCN or Acid CN. 25 
Table 1: Relative increase in intracellular Ca2+ in human embryonic 
kidney 293 (HEK 293A) cells expressing the 5-HT2C receptor treated with 
unhydrolysed and hydrolysed sodium caseinate (NaCN), acid casein 
(Acid CN), skim milk powder (SMP) and glycomacropeptide (GMP), and 
simulated intestinal digestion (SID) of the sodium caseinate hydrolysate 30 
NaCNH-240 min 
Sample * Relative increase in intracellular 
Ca2+ (% RFU) † 
Hek-5-HT2c-INI Hek-5-HT2c-VSV 
NaCN 2.0 ± 1.0a -3.1 ± 1.0a 
NaCNH-240 min 94.9 ± 3.1c 82.7 ± 3.1c 
Acid CN -0.3 ± 3.0a 2.2 ± 1.1a 
Acid CNH-240 min 66.1 ± 5.5b 38.4 ± 25.1b 
SMP 4.5 ± 2.8a 5.0 ± 3.8a 
SMPH-240 min 42.6± 21.4b 9.8 ± 6.4a 
GMP 43.4 ± 7.8b 11.3 ± 2.9a 
GMPH-240 min 93.0 ± 18.3c 74.7 ± 22.1c 
NaCNH-SID 57.4 ± 5.3b nd 
nd: not determined 
* NaCN: sodium caseinate; NaCNH-240 min: 240 min sodium casein 
hydrolysate; Acid CN: acid casein; Acid CNH-240 min: 240 min acid 
casein hydrolysate; SMP: skim milk powder; SMPH-240 min: 240 min 35 
skim milk powder hydrolysate; GMP: glycomacropeptide; GMPH-240 
min: 240 min glycomacropeptide hydrolysate; NaCNH-SID: sample 
obtained following simulated intestinal digestion of NaCNH-240 min. All 
samples were tested at the concentration 0.5 mg.mL-1, except NaCN, 
NaCNH-240 min and NaCNH-SID which were tested at 1 mg.mL-1. 40 
† Relative increase in fluorescence units compared to the positive control 
5–hydroxytryptamine tested at 10 nM. Average values (n=3) ± SD. 
Within the same column, values with different letters are significantly 
different (P < 0.05) 
 45 
 Different fractionation procedures were applied to NaCNH-
240 min hydrolysate in order to study the physicochemical 
properties of the bioactive peptides within this hydrolysate. 
3.3. Fractionation of NaCNH-240 min by membrane 
fractionation, SPE, IEF and semi-preparative RP-HPLC 50 
Membrane fractionation of NaCNH-240 min was carried out 
using a UF procedure where different MWCO membranes were 
employed (5 and 1 kDa). Four fractions with different molecular 
mass distribution profiles were obtained (Fig. 2a). As expected 
the 5 kDa retentate contained the proteinaceous material (> 5 55 
kDa) from NaCNH-240 min, whereas the 5 kDa permeate, 1 kDa 
retentate and 1 kDa permeate were free from proteins. The 
proportion of peptides less than 1 kDa was most abundant in the 1 
kDa permeate (80.4 %). The RP-HPLC profile of the 5 and 1 kDa 
permeates (Fig. 3c and 3d, respectively) showed a less complex 60 
peptide profile compared to that of NaCNH-240 min (Fig. 3b). 
This was due to the removal of large molecular mass peptides and 
proteins during the UF procedure. In addition, some peptide 
peaks were more abundant in the 5 and 1 kDa permeate compared 
to the NaCNH-240 min hydrolysate, showing enrichment in low 65 
molecular mass peptides upon UF. The volume concentration 
ratio (VCR) obtained following UF treatment with the 5 and 1 
kDa membranes was 5.8 and 2.1, respectively. The RP profiles 
obtained using UPLC showed a better resolution of peptide peaks 
in the NaCNH-240 min (Fig. 4a) compared to RP-HPLC (Fig. 70 
3b). 
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Fig 4: Reverse-phase ultra-performance liquid chromatography (RP-
UPLC) profiles of sodium caseinate hydrolysate (NaCNH-240 min), 
ultrafiltration (UF), solid phase extraction (SPE) and isoelectric focusing 
(IEF) fractions, and simulated intestinal digestion (SID) of the sodium 
caseinate hydrolysate NaCNH-240 min. (a) NaCNH-240 min (b) UF 5 5 
kDa permeate (c) SPE X-40% ACN (d) IEF 4 and (e) SID of NaCNH-240 
min. 
 
 Bioactivity of the UF fractions was determined (Fig. 2b). With 
the 5-HT2C-INI serotonin receptor, the retentates (5 and 1 kDa 10 
retentates) showed lower bioactivity than the permeates (5 and 1 
kDa permeate) and bioactivity of the 5 and 1 kDa permeates were 
similar. Slight differences were seen with the 5-HT2C-VSV 
serotonin receptor where bioactivity was lowest with the 5 kDa 
retentate, whereas the 5 kDa permeate, 1 kDa retentate and 1 kDa 15 
permeate displayed similar bioactivities. Dose response curves 
depicting 5-HT2C receptor mediated intracellular calcium influx 
following exposure to NaCNH-240 min, and its associated 5 and 
1 kDa permeates are illustrated on Fig. 5. A dose response 
relationship between the increase in intracellular calcium and the 20 
concentration of test substance was seen for these three samples, 
with the 5 and 1 kDa permeate both showing higher bioactivity 
than NaCNH-240 min. This result is in agreement with the 
enrichment in peptides observed upon UF fractionation. The 5 
and 1 kDa permeates essentially showed superimposable dose 25 
response curves, suggesting that the bioactive peptides had the 
same potency in both UF fractions of NaCNH-240 min. 
 
 
 30 
 
 
 
 
 35 
 
 
 
Fig 5: Dose response curves of sodium casein hydrolysate (NaCNH-240 
min) and associated ultrafiltration fractions (UF 5 kDa permeate and UF 1 40 
kDa permeate) on their 5-HT2C induced calcium influx. Each point is the 
average of two measurements (confidence interval at 5 %: 8.1, 6.5 and 3.4 
% for NaCNH-240 min, UF 5 and 1 kDa permeate, respectively) of 
relative increase in intracellular Ca2+ in human embryonic kidney 293 
(HEK 293A) cells. 45 
 The NaCNH-240 min hydrolysate was fractionated with SPE 
as described by Nongonierma and FitzGerald.49 Recovery of 
peptide material using this procedure was 77.5 %.  
Table 2: Relative increase in intracellular Ca2+ in 5-HT2C expressing 
human embryonic kidney 293 (HEK 293A) cells treated with sodium 50 
caseinate hydrolysate (NaCNH-240 min), fractions obtained on elution 
from solid-phase extraction (SPE) Strata X with different acetonitrile 
(ACN) concentrations and isoelectric focusing (IEF) fractions. 
Sample* Relative increase in intracellular Ca2+ 
(% RFU)† 
 Hek-5-HT2c-INI Hek-5-HT2c-VSV 
NaCNH-240 min 94.9± 3.1c 78.1 ± 14.4b 
SPE X- unbound nd 3.7 ± 1.4a 
SPE X- 5 % ACN nd 0.9 ± 0.5a 
SPE X- 10 % ACN nd 2.7 ± 1.1a 
SPE X- 15 % ACN nd 2.6 ± 0.7a 
SPE X- 20 % ACN nd 3.7 ± 1.0a 
SPE X- 25 % ACN nd 3.9 ± 0.6a 
SPE X- 30 % ACN nd 5.4 ± 2.9a 
SPE X- 35 % ACN nd 90.5 ± 8.8b,c 
SPE X- 40 % ACN nd 86.7 ± 7.2b,c 
SPE X- 45 % ACN nd 99.4 ± 11.0c 
SPE X- 50 % ACN nd 98.7 ± 19.2c 
NaCNH-240 min + 
electrolyte 
71.1 ± 5.8b 75.9 ± 7.4b 
IEF 1 -8.5 ± 1.3a -4.3 ± 1.9a 
IEF 2 -3.8 ± 1.6a -5.1 ± 4.3a 
IEF 3 75.4 ± 7.5b 82.6 ± 10.0b,c 
IEF 4 95.7 ± 13.6c 100.9 ± 8.5c 
nd: not determined 
* SPE X : fractions obtained on elution from solid-phase extraction with 55 
Strata X with different acetonitrile (ACN) concentrations; IEF: isoelectric 
focusing fractions. All fractions were tested at 1 mg.mL-1. 
† Relative increase in fluorescence units compared to the positive control 
5–hydroxytryptamine tested at 10 nM. Average values (n=3) ± SD. 
Within the same column, values with different superscript letters are 60 
significantly different (P < 0.05) 
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 Although some peptide/protein material was lost during the 
SPE procedure, bioactivity was still seen within some of the 
fractions collected. Of the eleven fractions generated, the four 
fractions eluted between 35 and 50 % ACN activated the 5-HT2C-
VSV serotonin receptor (Table 2). Activation observed with the 5 
fractions eluted with 35 and 40 % ACN was not significantly 
different from that of NaCNH-240 min (P ≥ 0.05). A significantly 
higher activation was observed with the fractions eluted at 45 and 
50 % ACN compared to NaCNH-240 min (P <0.05). Activation 
induced by the fractions eluted between 35 and 50 % ACN was 10 
not significantly different (P ≥ 0.05). The RP profile of the SPE 
X – 40 % ACN fraction is shown in Fig. 4c. A lower number of 
peptide peaks is seen in this fraction compared to that of NaCNH-
240 min (Fig. 4a) and its 5 kDa permeate (Fig. 4b). In addition, 
no peptide peaks with an elution time less than 15 min could be 15 
seen on the RP profile of SPE X – 40 % ACN which is in 
agreement with its relatively hydrophobic nature. Fractionation 
by IEF showed that two fractions out of four were bioactive. 
These were the fractions with the highest pH value, i.e. pH 8.6 
and 13.2 (Table 2). 20 
  
 
 
 
 25 
 
 
 
 
 30 
 
 
 
 
 35 
 
 
 
 
 40 
 
 
Fig 6: Semi-preparative reverse-phase high performance liquid 
chromatography (RP-HPLC) profile of the sodium caseinate hydrolysate 
NaCNH-240 min (a) and relative increase in intracellular Ca2+ in human 45 
embryonic kidney 293 (HEK 293A) cells expressing the 5-HT2C receptor 
observed with the semi-preparative RP-HPLC fractions F1 to F11 (b). 
Values with different superscript letters are significantly different (P < 
0.05) 
The electrolyte (Biolyte 3/10) employed to carry out the IEF 50 
fractionation did not seem to interfere with the assay as shown by 
the similar intracellular calcium values obtained with NaCNH-
240 min with and without electrolyte with the 5-HT2C-VSV 
serotonin receptor (P ≥ 0.05, Table 2). The RP-UPLC profile of 
IEF 4 (Fig. 4d) shows a wide range of peptide peaks eluting at 55 
different retention times. The RP profile of IEF 4 is also less 
complex than that of NaCNH-240 min. Bioactivity of this 
fraction was significantly higher than that of NaCNH-240 min 
with the 5-HT2C-VSV serotonin receptor (P < 0.05, Table 2) 
whereas bioactivity of IEF 3 was not significantly different from 60 
NaCNH-240 min (P ≥ 0.05, Table 2). 
 
The fourth fractionation method used was semi-preparative RP-
HPLC, which allowed isolation of 11 fractions with different 
peptide composition (Fig. 6a). Out of the 11 fractions isolated, 65 
the five fractions eluting between 31.5 (22.8% ACN- F5) and 84 
min (69.5 % ACN- F10) were bioactive (Fig. 6b). 
3.4. Simulated intestinal digestion of NaCNH-240 min 
A SID protocol was applied to NaCNH-240 min to study its 
stability to intestinal proteinase/peptidase activities. The RP-70 
UPLC profile of NaCNH-SID (Fig. 4e) shows a significantly 
different peptide profile than NaCNH-240 min (Fig. 4a). The 
NaCNH-SID was still able to activate 5-HT2C-INI serotonin 
receptor (Table 1) indicating that bioactive peptides within 
NaCNH-240 min may survive intestinal digestion in vivo. In 75 
addition, activation of the serotonin 5-HT2C-INI receptor was not 
significantly different for NaCNH-SID and NaCNH-240 min (P ≥ 
0.05), which may suggest that the bioactive peptides within 
NaCNH-240 min are not further hydrolysed by the pancreatic 
enzyme activity or that their breakdown products are still able to 80 
stimulate serotonin 5-HT2C receptors in the same fashion as the 
parent peptides.  
4. Discussion 
Different effects of milk proteins on serotonin release have been 
described in the literature. Human and bovine -casomorphin-7 85 
(Tyr-Pro-Phe-Pro-Gly-Pro-Ile) was shown to act as a 5-HT2-
serotonin receptor antagonist.58 In addition, milk proteins such as 
-lactalbumin are a good source of Tryptophan (Trp), the 
precursor of serotonin. When diets rich in -lactalbumin were 
administered to rats, an increase in the production of serotonin 90 
was seen. However, this did not translate into increased levels of 
extracellular serotonin.59 Ingestion of -lactalbumin has been 
correlated with an increase in hypothalamic serotonin release in 
rats59 and in humans,60 which has been linked to the high Trp 
content of -lactalbumin compared to other milk proteins. 95 
Ingestion of -lactalbumin has been correlated with a higher 
bioavailability of Trp which is the precursor of serotonin.61 To 
our knowledge, milk-derived bioactive peptides demonstrating 
direct 5-HT2C serotonin receptor activation have not been 
reported in the literature to date. This study describes the 100 
generation of different milk protein hydrolysates and analyses 
their potential to increase intracellular calcium in HEK 293A 
cells engineered to express the 5-HT2C receptor. An increase in 
the activation of 5-HT2C serotonin receptor was seen over the 
time course of NaCN hydrolysis (Fig. 2b). Protein breakdown 105 
increased between 10 and 240 min (Fig. 2a), suggesting that 
release of bioactive peptides in time may have been responsible 
for the higher 5-HT2C serotonin receptor activation observed. 
Hydrolysis has the potential to release specific peptide sequences 
with bioactive potential, previously encrypted within the protein 110 
structure.48 As expected, enrichment in bioactive peptides 
correlated with the enrichment of smaller molecular mass 
peptides following the two UF steps. Bioactivity was found in the 
5 and 1 kDa retentates possibly due to the fact that they still 
contained bioactive peptides as the UF procedure employed did 115 
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not include a diafiltration step. The dose response curves 
confirmed that the 5 and 1 kDa permeates were more potent than 
NaCNH-240 min (Fig. 5). No difference in potency was seen 
between the 5 and 1 kDa permeates, suggesting that bioactive 
peptides could be found within both fractions at similar 5 
concentrations. Similar potency in both fractions may also be 
related to the fact that their peptide composition does not 
dramatically differ, this was confirmed with the RP-HPLC (Fig. 
3c and 3d) and molecular mass distribution profiles (Fig. 2a). 
 Milk protein hydrolysates generated with other starting 10 
materials were investigated for their potential to activate 
serotonin receptors. Unhydrolysed proteins such as Acid CN or 
SMP could not substantially activate the 5-HT2C serotonin 
receptor (Table 1). GMP was shown to have 5-HT2C receptor 
activating potential both in unhydrolysed and hydrolysed format 15 
(Table 1). GMP is a peptide which is released upon hydrolytic 
activity of chymosin notably during the renneting stage employed 
in the cheese making process. This peptide has been identified for 
its satiating properties when administered in vivo. Inhibition of 
gastric secretion and increased release of cholecystokinin (CCK) 20 
have been linked to the positive role of GMP on satiety.4,62,63 
Nevertheless, this satiating effect of GMP does not always 
translate to a reduction of food intake.64 Preload drinks containing 
whey proteins and GMP have been shown to enhance fullness 
ratings in human subjects compared to carbohydrates.64 However, 25 
no differences in food intake at the lunch meal could be 
determined between the protein and carbohydrate preload.64 
Other conflicting results are reported in the literature notably 
when GMP was administered as a preload, showing no impact on 
satiety.65 GMP was shown to increase the release of CCK, 30 
thereby mediating satiety signals in vivo.24 A different 
mechanism is described here where GMP acts as an agonist for 
serotonin receptors. To our knowledge this is the first time that 
GMP has been shown to bind and activate the 5-HT2C serotonin 
receptor. Furthermore, significantly higher 5-HT2C serotonin 35 
receptor activation could be found with GMPH-240 min 
compared to GMP (P < 0.05). Enzymatic hydrolysis of GMP 
resulted in an increase in bioactivity. It is unlikely that intact 
GMP will reach the target serotonin receptors which are located 
in the enteric nervous system. Whereas hydrolysates, which 40 
contain lower molecular mass fragments, may cross the gut 
barrier and reach target organs outside of those present within the 
gut, provided that they are not degraded within the gut. This may 
be of significance for the management of satiety using GMP. By 
hydrolysing GMP, we demonstrated that the generation of 45 
bioactive peptides with serotonergic properties could be achieved. 
Therefore, GMP and GMP hydrolysates may have potential as 
multi-functional ingredients in weight management targeting both 
the gut as well as the enteric nervous system. However, it was 
shown that GMP alone is not critical in pre-meal whey-induced 50 
satiety. Nevertheless, it may have a unique role in compensatory 
intake regulation managing daily energy intake.66 
 The stability of bioactive peptides to gastro-intestinal 
proteinases is a prerequisite for bioactivity in vivo.67 SID of 
NaCNH-240 min was carried out in order to study the stability of 55 
the bioactive peptides to intestinal enzymes. There was no 
significant difference (P ≥ 0.05) between the bioactive properties 
of NaCNH-SID and NaCNH-240 min (Table 1). This result 
suggests that the bioactive peptides present within NaCN-240 
min are likely to display their effect in vivo. It has also been 60 
suggested that different formulations, including the utilisation of 
surfactant agents, may be utilised to increase permeation of 
bioactive peptides in the gastro-intestinal tract.67 
 Four fractionation techniques including UF, SPE, semi-
preparative RP-HPLC and IEF were applied to NaCNH-240 min 65 
in order to better characterise the bioactive peptides within this 
hydrolysate. UF fractionation yielded 4 fractions which were all 
able to stimulate 5-HT2C serotonin receptor. However, the most 
potent samples were the 5 and 1 kDa permeates (Fig. 2b). Low 
molecular mass peptides can passively diffuse through the UF 70 
membranes. Recovery for the SPE procedure was of the same 
order as other studies.50 For the SPE fractionation, fractions 
eluted with ACN concentrations between 35 and 50 % (v/v) were 
bioactive (Table 2), which was in agreement with the results 
obtained with semi-preparative RP-HPLC with bioactive 75 
fractions eluting between 22.8 and 69.5 % ACN (Fig. 6). SPE and 
semi-preparative RP-HPLC both allowed isolation of a restricted 
number of bioactive fractions. SPE allowed fractionation of 
larger quantities (> 6 times more) than semi-preparative RP-
HPLC. Isoelectric focusing also showed bioactivity in different 80 
fractions (pH 8.6 and 13.2 for IEF3 and IEF4, respectively), 
whereas no bioactivity was found within the lower pH fractions 
(pH 0.9 and 2.9 for IEF1 and IEF2, respectively). Significant 
peptide losses (up to 40 %) were reported following precipitation 
during an IEF procedure.68 Similarly, during the fractionation 85 
procedure used in this study, overall losses of 37.8 % were 
obtained. The pH range for NaCNH-240 min fractions (between 
0.5 and 13.6) was broader than that reported by Yata et al.68 
(between pH 3.0 and 10.0) with the same ampholyte Bio-lyte 
3/10. Differences in pH range compared to Yata et al.68 are likely 90 
due to composition differences between both hydrolysates, with 
low pH values possibly due to the HCl employed during pH stat 
control of NaCNH-240 min. Fractions displaying bioactive 
properties had a higher pH, i.e., 8.6 and 13.2. Previous studies 
have described the utilisation of autofocusing (IEF conducted 95 
without ampholyte) in the isolation of bioactive peptides, notably 
for their immunostimulatory properties.51,52 Fractions isolated by 
Mercier et al.52 induced a higher lymphocyte secretion compared 
to the parent hydrolysate. This was explained by the fact that 
peptide-peptide interactions (hydrophobic and electrostatic 100 
interactions) can occur in milk protein hydrolysates,69 resulting in 
lower bioactive potential of hydrolysates compared to fractions,52 
which may have occurred within NaCNH-240 min herein. In 
addition, enrichment of bioactive peptides upon fractionation 
could be seen following analysis of the RP-UPLC profiles of 105 
these fractions (data not shown). No significant difference (P ≥ 
0.05) could be seen between the bioactivity of NaCNH-240 min 
and IEF 3 whereas IEF 4 was more potent (P < 0.05) than 
NaCNH-240 min (Table 2). Saturation of the intracellular 
calcium measured may have been reached in the assay with 110 
certain fractions. However, it is expected that IEF 3 and IEF 4 
would yield more potent fractions than NaCNH-240 min as was 
seen with the UF permeates (Fig. 5). 
 The different fractionation techniques studied allowed us to 
establish that low molecular mass peptides with hydrophobic 115 
characteristics and a basic isoelectric point (pI) were able to 
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stimulate the 5-HT2C serotonin receptor in a HEK 293A cell 
culture model. Bioavailability of the peptides is crucial for their 
bioactivity as the target 5-HT2C serotonin receptors are located in 
the enteric nervous system. It has been demonstrated that 
intestinal transport of intact peptides and even proteins occur in 5 
vivo.70 Intact peptides can be absorbed in the gastro-intestinal 
tract when they are stable to gastro-intestinal enzymes and are 
able to permeate through the intestinal mucosa.70 Relatively 
hydrophobic peptides from milk such as Leu-Trp, Phe-Tyr, Ile-
Tyr and Ile-Pro-Pro could reach the circulation without being 10 
degraded in the gastrointestinal tract.71 The small size of the 
bioactive peptides found within NaCNH-240 min may allow 
them to cross the gut barrier.72 SID of NaCNH-240 min revealed 
that bioactivity was maintained, which may suggest that in vivo, 
the bioactive components in the NaCNH-240 min hydrolysate 15 
would have the potential to survive intestinal digestion. In 
addition, the hydrophobic nature of the bioactive peptides of 
NaCNH-240 min make them good candidates for intestinal 
permeation.73 Fractionation with IEF has demonstrated that the 
bioactive peptides within NaCNH-240 min have an isolelectric 20 
pH between 8.6 and 13.2, which suggests that these peptides will 
remain in solution in the small intestinal lumen which has been 
found to be between pH 5.5 and 7.6 in healthy subjects.74 More 
research is needed on the role of these bioactive peptides on 
regulation of food intake. 25 
5. Conclusions 
The potential of a range of milk protein hydrolysates to activate 
serotonin receptors has been demonstrated in vitro. In most cases, 
enzymatic hydrolysis of the milk protein substrates was a 
prerequisite for 5-HT2C serotonin receptor activation. However, 30 
intact GMP behaved as an agonist and was able to stimulate 5-
HT2C serotonin receptors. The 5-HT2C serotonin receptor 
activation obtained with the GMP hydrolysate (GMPH-240 min) 
was however higher than that with GMP. Isolation of bioactive 
fractions of NaCNH-240 min allowed a better characterisation of 35 
the physicochemical properties of the bioactive peptides present 
within this hydrolysate. The small size, hydrophobic nature and 
basic pI of the bioactive peptides within NaCNH-240 min, 
together with the maintenance of bioactivity following SID 
suggest that these compounds are good candidates for intestinal 40 
absorption in vivo. Further studies on the in vivo effect on food 
intake are now warranted. Optimal dosage of NaCNH-240 min 
needs to be determined in humans in order to further formulate 
functional foods and dietetic products. The outcomes of this 
research indicate that milk-derived peptides may have potential as 45 
natural ingredients in the formulation of food-products designed 
to help in weight management. 
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